DBV Technologies S.A.
DBV Technologies S.A. (DBVT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DBVT · as of Sep 30, 2025
Ownership Breakdown
33
Institutional Holders
▲ 4 vs Q2
$65.19M
Total Inst. Value
▼ $1.03M vs Q2
23.92M
Shares Outstanding
freeFloat 60.78%
6.52M
13F Shares Held
▼ 713,353 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DBVT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 1.46M | 7.60% | 7.60% | $14.61B | Nov 14, 2025 | — held |
VIVO CAPITAL, LLC biological products, (no diagnostic substances) | 1.05M | 5.48% | 5.48% | $10.55B | Nov 14, 2025 | — held |
BIOIMPACT CAPITAL LLC biological products, (no diagnostic substances) | 1.05M | 5.48% | 5.48% | $10.55B | Nov 14, 2025 | — held |
OCTAGON CAPITAL ADVISORS LP biological products, (no diagnostic substances) | 1.02M | 5.29% | 5.29% | $10.18B | Nov 14, 2025 | — held |
YIHENG CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 656.3K | 3.41% | 3.41% | $6.56B | Nov 14, 2025 | — held |
GREAT POINT PARTNERS LLC biological products, (no diagnostic substances) | 378.6K | 1.97% | 1.97% | $3.79B | Nov 14, 2025 | ▲ 3.9K |
ADAGE CAPITAL PARTNERS GP, L.L.C. biological products, (no diagnostic substances) | 345.9K | 1.80% | 1.80% | $3.46B | Nov 14, 2025 | ▼ 708.6K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 337.9K | 1.76% | 1.76% | $3.38B | Nov 14, 2025 | ▲ 69.8K |
ARTISAN PARTNERS LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 51.9K | 26.99% | 26.99% | $519.20M | Nov 12, 2025 | NEW |
NAN FUNG TRINITY (HK) LTD biological products, (no diagnostic substances) | 37.1K | 19.29% | 19.29% | $370.95M | Nov 4, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+99.6K shares7
New Positions
first time holders6
Decreased
−882.5K shares4
Sold Out
fully exitedNet shares change (top 50)
782.9K
+99.6K / −882.5K
Net new holders
+4
7 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DBVT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
1
Sell transactions
2.00
Buy/Sell ratio
$25M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Mohideen Pharis Chief Medical Officer | Jan 29, 2026 | Sale | 534 | $4.86 | $2.6K | 145.0K | Form 4 ↗ |
EPIC Bpifrance Member of 10% owner group | Dec 17, 2025 | Sale | 2,036,990 | $4.84 | $9.86M | 8.64M | Form 4 ↗ |
EPIC Bpifrance Member of 10% owner group | Dec 17, 2025 | Sale | 40,000 | $5.28 | $211.2K | 8.60M | Form 4 ↗ |
EPIC Bpifrance Member of 10% owner group | Dec 18, 2025 | Sale | 1,292,103 | $4.19 | $5.41M | 7.30M | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 21, 2025 | Award | 253,000 | $2.90 | $733.7K | 253.0K | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 21, 2025 | Award | 44,000 | — | — | 145.5K | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 20, 2025 | Sale | 6,496 | $2.88 | $18.7K | 103.2K | Form 4 ↗ |
Mohideen Pharis Chief Medical Officer | Nov 21, 2025 | Sale | 1,624 | $2.77 | $4.5K | 101.5K | Form 4 ↗ |
Boucinha Virginie Chief Financial Officer | Nov 21, 2025 | Award | 192,000 | $2.90 | $556.8K | 192.0K | Form 4 ↗ |
Boucinha Virginie Chief Financial Officer | Nov 21, 2025 | Award | 32,000 | — | — | 70.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
DBV Technologies S.A. (DBVT) is primarily owned by institutional investors, who hold approximately 27.3% of total shares outstanding. Company insiders own approximately 39.22%, while retail and public investors account for the remaining 33.53%.
The largest institutional shareholder of DBV Technologies S.A. is BAKER BROS. ADVISORS LP, holding approximately 1.46 million shares — equal to 7.60% of outstanding shares — as of September 30, 2025.
A total of 33 institutional investors currently hold DBVT stock, with a combined institutional value of approximately $65,192,849 as of the most recent 13F filing period.
Frequently asked questions
DBVT ownershipDBV Technologies S.A. (DBVT) is primarily owned by institutional investors, who hold approximately 27.3% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 7.60% stake. Company insiders hold 39.22%. Data sourced from SEC Form 13F as of September 30, 2025.